BETA
Your AI-Trained Oncology Knowledge Connection!
Multiple Myeloma
Stay up to date on practice-changing data in community practice.
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.
Read More
Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Listen
Newer Approaches Show Potential to Reduce Need for Transplant in NDMM
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Managing Dose Reductions With Bispecific Therapies in Myeloma
During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.
FDA Greenlights Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Linvoseltamab represents a promising new approach to treating multiple myeloma through immune-based therapy.
